Background illustration for clinical trials search

Paid Clinical Trials Pittsburgh

Discover 1,166 paid clinical trials in Pittsburgh, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for
Platinum-resistant Ovarian Cancer,
Location: Pittsburgh PA, Cleveland OH, Columbus OH,
Sponsor: Genelux Corporation

Sex: Female

Age: 18+

Code: NCT05281471

Phase 3, Recruiting
Active & Responsive

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

for
Primary Immune Thrombocytopenia (ITP),
Location: Pittsburgh PA, East Brunswick NJ, Summit NJ,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07421167

Phase 2, Recruiting
Active & Responsive

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for
Endometrial Cancer
Location: Pittsburgh PA, Fairfax VA, Brandywine MD, Doylestown PA,
Sponsor: Faeth Therapeutics

Sex: Female

Age: 18+

Code: NCT06463028

Phase 2, Recruiting
Active & Responsive

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for
Advanced Esophageal Adenocarcinoma,
Location: Pittsburgh PA, Monroeville PA, N. Huntingdon PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06203600

Phase 2, Phase 3, Recruiting
Active & Responsive

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Pittsburgh PA, Indiana PA, New Castle PA, Farrell PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT04671667

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Pittsburgh PA, Monroeville PA, Washington PA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06589804

Phase 3, Recruiting
Active & Responsive

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for
Autoimmune Disease, Crohn Disease, Dermatomyositis,
Location: Pittsburgh PA, Columbus OH, Bethesda MD,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03816345

Phase 1, Recruiting
Active & ResponsiveNew

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

for
Cutaneous Melanoma
Location: Pittsburgh PA, Morgantown WV, Bridgeport WV,
Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 70+

Code: NCT07068074

Phase 3, Recruiting
Active & Responsive

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Pittsburgh PA, Cleveland OH, Charlottesville VA,
Sponsor: Parabilis Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05919264

Phase 1, Phase 2, Recruiting
Active & Responsive

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

for
Metastatic Hepatocellular Carcinoma,
Location: Pittsburgh PA, New York NY, Zion IL, Nashville TN,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06427941

Phase 1, Phase 2, Recruiting
Active & Responsive

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

for
Melanoma
Location: Pittsburgh PA
Sponsor: John Kirkwood

Sex: All

Age: 18+

Code: NCT06599619

Recruiting
Active & Responsive

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

for
Hepatocellular Carcinoma
Location: Pittsburgh PA
Sponsor: Anwaar Saeed

Sex: All

Age: 18+

Code: NCT06698250

Phase 2, Recruiting
Active & Responsive

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

for
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Location: Pittsburgh PA, St Louis MO, Seattle WA
Sponsor: Sawa Ito, MD

Sex: All

Age: 18+

Code: NCT06529731

Phase 2, Recruiting
Active & Responsive

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

for
Esophageal Squamous Cell Carcinoma
Location: Pittsburgh PA, East Syracuse NY, Tucson AZ,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05319730

Phase 1, Phase 2, Recruiting
Active & Responsive

Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

for
Synchronous Gastric Peritoneal Carcinomatosis,
Location: Pittsburgh PA
Sponsor: Mohammad Haroon Asif Choudry

Sex: All

Age: 18+

Code: NCT07475286

Phase 2, Recruiting
Active & Responsive

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

for
Lung Non-Small Cell Carcinoma
Location: Pittsburgh PA, Monroeville PA, N. Huntingdon PA,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07293247

Phase 2, Recruiting
Active & Responsive

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

for
Urothelial Carcinoma
Location: Pittsburgh PA, Cleveland OH, Toronto, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05562830

Phase 1, Phase 2, Recruiting
Active & Responsive

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for
Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM,
Location: Pittsburgh PA, Cleveland OH, Columbus OH, Fairfax VA,
Sponsor: Black Diamond Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07326566

Phase 2, Recruiting
Active & Responsive

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

for
Chronic Lymphocytic Leukemia, B-cell Malignancies
Location: Pittsburgh PA, Columbus OH, Florham Park NJ,
Sponsor: Curis, Inc.

Sex: All

Age: 18+

Code: NCT07271667

Phase 2, Recruiting
Active & Responsive

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

for
Pancreatic Adenocarcinoma
Location: Pittsburgh PA
Sponsor: Anwaar Saeed

Sex: All

Age: 18+

Code: NCT06896188

Phase 1, Recruiting